Regeneron shares fall after FDA rejects high-dose eye disease treatment
June 27, 2023 at 16:49 PM EDT
Regeneron said the rejection was "solely due to an ongoing review of inspection findings at a third-party filler."
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|